Key Points
- CEO David Bailey bought 32,134 KindlyMD shares at an average price of $5.59, investing approximately $179,629 and increasing his direct ownership to 32,134 shares.
- KindlyMD shares opened at $7.06 and were reported up 12.1%, but the stock remains highly volatile, with a 52-week range of $3.33 to $422.40 and a beta of 15.95.
- The company reported a $6.65-per-share quarterly loss on $35.87 million in revenue, with deeply negative margins. Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an average price target of $22.33.
KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) CEO David Bailey acquired 4,852 shares of the business's stock in a transaction dated Thursday, August 20th. The stock was purchased at an average price of $6.27 per share, with a total value of $30,422.04. Following the completion of the transaction, the chief executive officer directly owned 3,185,246 shares of the company's stock, valued at $19,971,492.42. This trade represents a 0.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
KindlyMD Stock Performance
Shares of NAKA stock opened at $7.06 on Friday. KindlyMD, Inc. has a 52-week low of $3.33 and a 52-week high of $422.40. The company has a market capitalization of $126.34 million, a PE ratio of -0.20 and a beta of 15.95. The business's fifty day moving average is $4.54 and its 200 day moving average is $7.24.
KindlyMD (NASDAQ:NAKA - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The business had revenue of $35.87 million for the quarter. On average, sell-side analysts forecast that KindlyMD, Inc. will post -11.31 EPS for the current fiscal year.
Hedge Funds Weigh In On KindlyMD
Large investors have recently modified their holdings of the company. Osaic Holdings Inc. bought a new stake in KindlyMD in the 2nd quarter worth approximately $215,000. Geode Capital Management LLC raised its stake in shares of KindlyMD by 76.2% during the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company's stock worth $484,000 after acquiring an additional 8,386 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of KindlyMD by 1,638.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company's stock worth $827,000 after acquiring an additional 31,245 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of KindlyMD in the 3rd quarter worth approximately $1,007,000. Finally, Vident Advisory LLC purchased a new stake in shares of KindlyMD in the 3rd quarter valued at $2,092,000.
Analysts Set New Price Targets
A number of research firms have commented on NAKA. Wall Street Zen raised shares of KindlyMD to a "sell" rating in a research note on Saturday, May 23rd. TD Cowen lifted their price objective on shares of KindlyMD from $1.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, July 27th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of KindlyMD in a report on Friday, August 7th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $22.33.
Check Out Our Latest Analysis on NAKA
KindlyMD News Roundup
Here are the key news stories impacting KindlyMD this week:
- Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
- Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
- Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
- Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data
KindlyMD Company Profile
(
Get Free Report)
Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
